Editorial Commentary
Bexmarilimab and azacitidine: promise for immunotherapy in myelodysplastic syndrome?
Annals of Blood
2026;
11:
20
.
(30 June 2026)
Editorial Commentary
Venetoclax and azacitidine in high-risk myelodysplastic syndromes: expectations vs. evidence
Annals of Blood
2026;
11:
19
.
(30 June 2026)
Editorial Commentary
Chronic graft-versus-host disease: toward mechanism-based prevention and treatment
Annals of Blood
2026;
11:
18
.
(30 June 2026)
Case Report
APTT dynamics after susoctocog alfa for early diagnostic support in suspected acquired hemophilia A: a case report
Annals of Blood
2026;
11:
17
.
(30 June 2026)
Case Report
Transfusion-acquired transient hemoglobinopathies: a case report and review of the literature
Annals of Blood
2026;
11:
16
.
(30 June 2026)
Case Report
Visual inspection of indeterminate crossmatch results prompted polyethylene glycol-enhanced antibody identification in a patient with poor hemoglobin response despite compatible transfusions: a case report
Annals of Blood
2026;
11:
15
.
(30 June 2026)
Review Article
Blood transfusion thresholds: a narrative review of the literature and recent guidelines
Annals of Blood
2026;
11:
14
.
(30 June 2026)
Review Article
Monoclonal B-cell lymphocytosis: what hematologists should know—a narrative review
Annals of Blood
2026;
11:
13
.
(30 June 2026)
Review Article
Transfusion practice in allogeneic hematopoietic stem cell transplantation: a narrative review of clinical guidelines and evidence gaps
Annals of Blood
2026;
11:
12
.
(30 June 2026)
Review Article
The history of hemoglobin-based oxygen carriers: a narrative review
Annals of Blood
2026;
11:
11
.
(30 June 2026)
Editorial Commentary
Optimizing quadruplet therapy for older patients with newly diagnosed multiple myeloma: lessons from the REST trial
Annals of Blood
2026;
11:
10
.
(30 March 2026)
Editorial Commentary
Low dose radiation in indolent lymphoma: from dose optimization to biological insight
Annals of Blood
2026;
11:
9
.
(30 March 2026)
Editorial Commentary
Improved therapy for paroxysmal nocturnal hemoglobinuria
Annals of Blood
2026;
11:
8
.
(30 March 2026)
Editorial Commentary
Driving CAR-T therapy down the GPRC5D fast lane
Annals of Blood
2026;
11:
7
.
(30 March 2026)
Editorial Commentary
Ferritin-guided iron supplementation as a paradigm shift in blood donor care: advancing donor iron management through evidence-based supplementation
Annals of Blood
2026;
11:
6
.
(30 March 2026)
Case Report
Concurrent immune thrombocytopenia and amyotrophic lateral sclerosis with transient improvement in both conditions following efgartigimod: a case report
Annals of Blood
2026;
11:
5
.
(30 March 2026)
Case Report
Multiple crossmatch-incompatible red blood cell transfusions in a patient with anti-Yta (Cartwright) antibodies without hemolytic transfusion reactions: case report
Annals of Blood
2026;
11:
4
.
(30 March 2026)
Review Article
Plasma-derived medicinal products: a narrative review of the multi-layered approach to ensuring pathogen safety
Annals of Blood
2026;
11:
2
.
(30 March 2026)
Review Article
New developments and future trends of artificial blood
Annals of Blood
2026;
11:
1
.
(30 March 2026)
Review Article
The modern role of corticosteroids in immune thrombotic thrombocytopenic purpura
Annals of Blood
2025;
10:
26
.
(30 December 2025)
Review Article
A holistic view of international regulations and industry standards governing collection of plasma and manufacture of plasma-derived medicinal products
Annals of Blood
2025;
10:
25
.
(30 December 2025)
Review Article
The blood feud: compensated versus non-compensated source plasma donations
Annals of Blood
2025;
10:
24
.
(30 December 2025)
Review Article
A primer on pain in sickle cell disease: a literature review
Annals of Blood
2025;
10:
23
.
(30 December 2025)
Review Article
Source plasma apheresis and plasma-derived medicinal products: a historical review
Annals of Blood
2025;
10:
22
.
(30 December 2025)
